Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial

K. L. Lai, D. M. Niddam, J. L. Fuh, S. P. Chen, Y. F. Wang, W. T. Chen, J. C. Wu, S. J. Wang*

*此作品的通信作者

研究成果: Article同行評審

33 引文 斯高帕斯(Scopus)

摘要

Objectives: Chronic migraine (CM) is a prevalent and devastating disorder with limited therapeutic options. This study explored the efficacy of 10 mg/d flunarizine for CM prophylaxis as compared with 50 mg/d topiramate. Methods: We conducted a prospective, randomized, open-label, blinded-endpoint trial. Patients with CM were randomized to flunarizine and topiramate treatment. The primary outcomes assessed were the reductions in the total numbers of headache days and migraine days after 8 weeks of treatment. Secondary outcomes were reductions in the numbers of days of acute abortive medication intake and acute abortive medication tablets taken, and the 50% responder rate. Results: Sixty-two subjects were randomized (n=31/group). Patients treated with flunarizine showed significant reductions in the numbers of total headache days (−4.9 vs −2.3, P=.012) and migraine days (−4.3 vs −1.4, P=.001) compared with those treated with topiramate. Patients treated with flunarizine also showed significant reductions in the numbers of days of acute abortive medication intake (−2.3 vs −0.2, P=.005) and acute abortive medication tablets taken (−4.6 vs −0.5, P=.005) and had a higher 50% responder rate in terms of total headache days (58.6% vs 25.9%, P=.013) and migraine days (75.9% vs 29.6%, P=.001), compared with topiramate-treated patients. Flunarizine was generally well tolerated and had a safety profile comparable to that of topiramate. Conclusions: Our results suggest that, in an 8-week study, 10 mg/d flunarizine is more effective than 50 mg/d topiramate for CM prophylaxis.

原文English
頁(從 - 到)476-483
頁數8
期刊Acta Neurologica Scandinavica
135
發行號4
DOIs
出版狀態Published - 1 4月 2017

指紋

深入研究「Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial」主題。共同形成了獨特的指紋。

引用此